Mannkind Corp. bets on inhaled insulin
Mannkind Corp. is betting that its inhalable insulin will be a hit with diabetes patients despite Pfizer's decision to stop selling a similar product.
Mannkind Chief Executive Alfred E. Mann said his inhalable insulin is medically superior to the product Pfizer pulled of the market last month because of poor sales, The Los Angeles Times reported Friday. The newspaper said Mann is putting nearly $1 billion of his own money on the effort.
"I believe this is one of the most valuable products in history in the drug industry, and I'm willing to back it up with my estate," Mann said.
MannKind, which is based in Valencia, Calif., is in the final stage of clinical trials for Technosphere Insulin. Mann said the company would be ready by the end of next year to apply for federal approval to sell the drug for Type 1 and Type 2 diabetes. // Copyright 2007 by United Press International
- Diet 'can reverse kidney failure' in mice with diabetes
- US health care: Older colon cancer patients not to be offered chemo
- Study: Death rates higher for elderly ICU patients in U.S.
- Drug maker of Avandia accused of false advertising (video)
- Doctors in America in short supply (video)
- What the world's healthiest people eat
- Doctors Urge Use of Diabetes Blood Test
- Medical Centers Target Chronic Diseases in Developing Countries
- Number of cancer-ill patients increased by ten per cent last year, against 2006
- Review shows smoking linked to diabetes
- Naked photo shoot planned for Mexico City
- Kerry Katona expecting another girl
- Anna Nicole Smith's body in morgue amid court fight
- Johnny Knoxville has confessed he has a small penis
- Nude Britney Spears on Bearskin Rug
- Captive Natascha Kampusch was sexually abused - Images
- Angelina Jolie till sleeps with Jenny Shimizu
- Fire of raunchy photos Katie Rees Miss Nevada
- Sex scandal: Romanian consul in Moldova caught on tape
- World's smallest baby to be released from hospital